Cefcapene
Chemical compound
- J01DD17 (WHO)
- In general: ℞ (Prescription only)
- (6R,7R)-3-{[(Aminocarbonyl)oxy]methyl}-7-{(Z)-[2-(2-amino-4-thiazolyl)-1-oxo-2-pentenyl]amino}-8-oxo-5-thia-1-azabicyclo(4.2.0)oct-2-ene-2-carboxylic acid
- 135889-00-8 Y
- 6436055
- 4940731 N
- 4D5D3422MW
- D07638 Y
- CHEBI:131729 N
- ChEMBL582912 N
- Interactive image
- O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)C(=C/CC)\c3nc(sc3)N)COC(=O)N)C(=O)O
InChI
- InChI=1S/C17H19N5O6S2/c1-2-3-8(9-6-30-16(18)20-9)12(23)21-10-13(24)22-11(15(25)26)7(4-28-17(19)27)5-29-14(10)22/h3,6,10,14H,2,4-5H2,1H3,(H2,18,20)(H2,19,27)(H,21,23)(H,25,26)/b8-3-/t10-,14-/m1/s1 N
- Key:HJJRIJDTIPFROI-NVKITGPLSA-N N
Cefcapene (INN) is a third-generation cephalosporin antibiotic.
It was patented in 1985 and approved for medical use in 1997.[1]
References
- ^ Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 496. ISBN 9783527607495.
- v
- t
- e
(inhibit synthesis
of peptidoglycan
layer of bacterial
cell wall by binding
to and inhibiting
PBPs, a group of
D-alanyl-D-alanine
transpeptidases)
Glycopeptides Lipoglycopeptides |
|
---|---|
Lipopeptides |
|
Polymyxins |
|
Other |
|
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition (Fosfomycin)
- DADAL/AR inhibitors (Cycloserine)
- bactoprenol inhibitors (Bacitracin)
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
This systemic antibiotic-related article is a stub. You can help Wikipedia by expanding it. |
- v
- t
- e